RxDoctor Payments Data

Bernard Weinbach, MD

Internal Medicine · Aventura, FLNPI 1417914219

Payments from drug & device makers

$2,987in general payments, 2019–2025

Across 88 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$728
  • Johnson & Johnson$469
  • AstraZeneca$342
  • Novartis$324
  • AbbVie$302
  • Pfizer$272
  • plus $550 from 13 others

What the payments were for

  • Food & beverage$2,981100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,987 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$161,989
Medicare patients
291
Services billed
2,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$89,081
XareltoRivaroxaban68$54,469
MyrbetriqMirabegron47$40,590
OzempicSemaglutide26$29,111
JardianceEmpagliflozin24$25,381
LinzessLinaclotide32$19,508
JanuviaSitagliptin Phosphate14$18,701
TrulicityDulaglutide16$13,913
GemtesaVibegron11$12,027
JentaduetoLinagliptin/Metformin Hcl12$6,844
Tiagabine Hcl24$6,631
LumiganBimatoprost15$3,912
SynthroidLevothyroxine Sodium34$3,730
Levothyroxine Sodium317$3,405
Atorvastatin Calcium371$2,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$89,08170 claims
Johnson & JohnsonXarelto$469$54,46968 claims
Astellas Pharma US IncMyrbetriq$25$40,59047 claims
Novo NordiskOzempic$728$29,11126 claims
AbbVieLinzess, Lumigan, Synthroid$302$27,15081 claims
MerckJanuvia$56$18,70114 claims
Lilly USA, LLCTrulicity$129$13,91316 claims
Sumitomo Pharma America, Inc.Gemtesa$169$12,02711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →